Cencora raises earnings guidance: 13 analysts rate Cencora stock Buy
Published on 10/05/2026 at 10:00 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
Cencora (ISIN US03073E1055) was trading at EUR 275.55 at Lang & Schwarz on October 5, 2026 at 9:48 a.m. CEST, plus 0.33 percent versus the prior close of EUR 274.65. The company raised fiscal 2026 adjusted earnings guidance to USD 17.75-17.95 per share from USD 17.70-17.90, while 13 analysts carried Buy ratings and three carried Hold ratings.
Guidance moves higher
According to Zacks on September 4, 2026, Cencora reported adjusted earnings per share of USD 4.48 in its fiscal third quarter of 2026, above the USD 4.37 consensus estimate. The comparison implies a 2.52 percent earnings beat.
The same report said fiscal third-quarter revenue reached USD 84.76 billion, up 5.10 percent year over year, while GAAP earnings per share increased to USD 3.94 from USD 3.52. Adjusted operating income rose 17.00 percent to USD 1.24 billion, but net interest expense increased 72.00 percent to USD 140.70 million.
Specialty operations drive growth
U.S. Healthcare Solutions revenue reached USD 74.90 billion in the fiscal third quarter of 2026, up 4.90 percent year over year, according to Zacks. Segment operating income rose 15.90 percent to USD 966.20 million, with specialty products, including GLP-1 medicines, supporting volume growth.
Cencora also expects fiscal 2026 revenue growth of 4.00-6.00 percent and adjusted operating income growth of 13.00-14.00 percent. The higher earnings range reflects stronger execution, although the report identified higher operating expenses and the loss of an oncology customer as counterweights.
Analyst view and next date
MarketBeat reported on October 4, 2026, that 13 analysts rated Cencora Buy and three rated it Hold, producing a Moderate Buy consensus and an average price target of USD 370.85. The same report cited adjusted earnings per share of USD 4.48 and revenue of USD 84.75 billion for the fiscal third quarter.
Simply Wall St lists November 4, 2026 as the date for Cencora's fiscal fourth-quarter results. That event will test whether the raised earnings range can be delivered after the third-quarter revenue increase and the acquisition-related cost pressure.
Stock remains below yearly high
Cencora stock was trading at EUR 275.55 at Lang & Schwarz on October 5, 2026 at 9:48 a.m. CEST, plus 0.33 percent versus the prior close of EUR 274.65 on October 2, 2026. The structured market quote showed a USD 60.1 billion market capitalization on October 2, 2026 and a 52-week range of USD 244.82 to USD 377.54.
The further course of trading is shown by the continuously updated real-time quote of Cencora stock.
Cencora stock facts
- Company: Cencora, Inc.
- ISIN: US03073E1055
- WKN: 766149
- Ticker: COR
- Primary exchange: NYSE
- Price Lang & Schwarz (as of October 5, 2026, 9:48 a.m. CEST): EUR 275.55
- Change versus prior close: plus 0.33 percent
- Prior close Lang & Schwarz (October 2, 2026): EUR 274.65
- Market capitalization: USD 60.1 billion (as of October 2, 2026)
- 52-week range: USD 244.82-377.54 (as of October 2, 2026)
- Sector / Industry: Healthcare / Medical - Distribution
- Next earnings date: November 4, 2026
